Epidiolex

GW Pharmaceuticals plc (NASDAQ: GWPH) reported its financial results Tuesday for the first quarter of fiscal 2019. The company reported revenue growth of  67.5 percent. One highlight: the report includes sales of the company's Epidiolex drug, which last year became the first cannabis-based...

Investors in GW Pharmaceuticals PLC (NASDAQ: GWPH) may need to sit through some short-term volatility as sales of the company's newly approved drug ramp up slowly because of insurance coverage issues, says the author of The 420 Investor. Alan Brochstein, who is a founding partner of New...

Bank of America Merrill Lynch doubled down on its bullish thesis for GW Pharmaceuticals plc (NASDAQ: GWPH) and its flagship Epidiolex drug after attending the American Epilepsy Society's annual meeting. The Analyst Analysts Tazeen Ahmad maintained a Buy on GW Pharma with a $190 price...

GW Pharmaceuticals plc (NASDAQ: GWPH) Epidiolex drug and earlier-stage programs Sativex and CBDV will represent major catalysts for the stock in the near-term, in Cantor Fitzgerald's view.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW Pharmaceuticals with a $211 price...

GW Pharmaceuticals plc (NASDAQ: GWPH) reported financial results for its fiscal fourth quarter 2018. Compared to analysts' consensus estimates, the company reported a better-than-expected net loss, but its top line missed the expectations. What Happened For the quarter ended Sept. 30, GW...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced incremental positive news on its lead cannabinoid product candidate Epidiolex, sending the stock higher. What Happened GW Pharma announcedpositive results for a second, late-stage study that evaluated its Epidiolex oral solution for treatment...

Leerink is taking a bullish stance on GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH), with a thesis centering around the company's lead drug Epidiolex; the drug Sativex; GW's involvement in the epilepsy market and its cannabinoid science platform. The Analyst Leerink's Marc Goodman...

The global cannabis industry took two big steps forward this week. On Oct. 31, Mexico’s Supreme Court said the laws that ban recreational weed are unconstitutional, essentially opening the door for a potential legalization of pot in the future. The second major development took place across...

Two big news items dominated the cannabis industry this week: the re-scheduling of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s cannabis-derived drug, Epidiolex, from the Schedule I category to the Schedule V category; and High Times’ acquisition of Dope Magazine for $11.2 million in...

Amid the controversies surrounding the legalization of cannabis and associated products, gradual advancements have been made this year. As of Sept. 27, a specific type of cannabidiol, or CBD oil will be federally legal in the United States. What Happened The U.S. Drug Enforcement Administration...

Even before word of the DEA's landmark rescheduling of cannabidiol (CBD) for GW Pharmaceuticals (NASDAQ: GWPH) FDA-approved Epidiolex, the cannabis market has had a hot summer. Medical cannabis is now legal in 31 states and the District of Columbia, with adult-use markets open in 9 of them plus...

By Sunday night, the U.S. Drug Enforcement Administration is expected to reclassify GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s Epidiolex to allow medicinal use. This could open the therapy to a new and promising market. The Analyst  Morgan Stanley analyst David Lebowitz ...

After a huge year in 2017, GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) stock has traded mostly sideways so far in 2018. But one analysts believes GW will soon return to its winning ways. The Analyst Stifel analyst Paul Matteis initiated coverage of GW Pharma with a Buy rating and $181 price target....

It was another extremely busy week for the cannabis industry. Voters in Oklahoma chose to legalize medical marijuana, becoming the 30th U.S. state to do so; GW Pharmaceuticals (NASDAQ: GWPH) got the first-ever FDA approval for a cannabis-based drug; Ice Cube’s Big3 basketball league...

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)'s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch.  The Analyst Bank of America'...